COAG Hemab Therapeutics Holdings, Inc.

NASDAQ
$39.15

Hemab Therapeutics Holdings, Inc. (COAG) is expected to report earnings on February 9, 2027, before the market open. The consensus earnings estimate is a loss of $0.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.3% since its last earnings release on November 10, 2026.

Hemab Therapeutics Missed Consensus Estimates
Tuesday, November 10, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.59)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $39.33

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.